Biomark Diagnostics (Biomark Diagnostics) EBIT per Share : $-0.01 (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biomark Diagnostics EBIT per Share?

Biomark Diagnostics's EBIT per Share for the three months ended in Dec. 2023 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01.

During the past 3 years, the average EBIT per Share Growth Rate was -7.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was -15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Biomark Diagnostics's EBIT per Share or its related term are showing as below:

BMKDF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -31 Med: -7.5 Max: 52.5
Current: -7.3

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Biomark Diagnostics was 52.50% per year. The lowest was -31.00% per year. And the median was -7.50% per year.

BMKDF's 3-Year EBIT Growth Rate is ranked worse than
64.04% of 178 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.55 vs BMKDF: -7.30

Biomark Diagnostics's EBIT for the three months ended in Dec. 2023 was $-0.29 Mil.

Biomark Diagnostics EBIT per Share Historical Data

The historical data trend for Biomark Diagnostics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics EBIT per Share Chart

Biomark Diagnostics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT per Share

Get a 7-Day Free Trial

-0.01

-0.02

Biomark Diagnostics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

Biomark Diagnostics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Biomark Diagnostics's EBIT per Share for the fiscal year that ended in Mar. 2023 is calculated as

	EBIT per Share		(A: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.266	/	82.778
=	-0.02

Biomark Diagnostics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.288	/	85.238
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

Biomark Diagnostics (OTCPK:BMKDF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Biomark Diagnostics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomark Diagnostics (Biomark Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

BUX:Canada

Address

130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2

Website

https://www.biomarkdiagnostics.com

Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines